On March 14, 2026, the international oncology journal Annals of Oncology (2025 IF: 65.4), the official journal of the European Society for Medical Oncology (ESMO), published the results of the international multicenter phase III OPTIMAL trial (NCT03315364). The study was led by Academician Binghe Xu (first author) from the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Professor S-B. Kim (corresponding author), with key contributions from Professor Tao Sun (Liaoning Cancer Hospital) and Professor H. Jeong (Asan Medical Center, University of Ulsan College of Medicine), among other international collaborators. For the first time, the study demonstrated that oral paclitaxel (DHP107) is non-inferior to weekly intravenous paclitaxel in first-line treatment of HER2-negative recurrent or metastatic breast cancer, with lower neurotoxicity and greater convenience—offering patients a safer and more accessible therapeutic option.